NASDAQ · CELC

Celcuity Inc.

$82.62 -$5.72 (-6.47%) 1D After hours
Session Pulse Overnight session 1 mentions on Tue · 0 bullish / 1 bearish tags No new SEC filings since Mon close its sector ranked 6/11 this week Full pulse →
Charting by TradingView

Key Metrics

$4.31B
Market cap
—
P/E · TTM
—
Revenue · TTM
−$192.89M
Net income
EPS · TTM $-4.48
Dividend yield —
Free cash flow −$172.93M
Beta · 1Y 1.29
EBITDA · TTM −$192.71M
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its May 4 high, the share price fell 43%.

    Peak close $144.98 on May 4; trough close $82.62 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -43%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 15
    The stock moved -17.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 15
  • Jun 2
    The stock moved -25.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 2

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$4.31B
Enterprise value$4.06B
Shares outstanding48.8M
52-wk range$34.30 – $151.02
Avg volume · 20D341.0K
Net cash $249.19M
Book value / share$1.24
IndustryServices-Medical Laboratories
ExchangeNASDAQ
About Celcuity Inc.
IPO dateSep 20, 2017
Employees155

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E—
P/S—
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №—

Profitability

Gross —
Operating —
Net —
FCF —
ROE / ROIC -228.1% · —

Financial Health

Current ratio12.31
Quick ratio—
Debt / equity2.58
Debt / EBITDA -0.72
Net cash $249.19M
Working capital$375.72M

Cash Flow · TTM

Operating CF −$172.49M
Capex −$438.00K
Free cash flow −$172.93M
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

—
Insufficient balance-sheet inputs

Graham Number vs Price

—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings